Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 83.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,488 shares of the company’s stock after selling 145,806 shares during the quarter. Voya Investment Management LLC owned about 0.07% of Keros Therapeutics worth $467,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KROS. JPMorgan Chase & Co. increased its position in shares of Keros Therapeutics by 585.9% during the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company’s stock worth $3,379,000 after purchasing an additional 182,314 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Keros Therapeutics in the fourth quarter valued at approximately $388,000. Barclays PLC boosted its holdings in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after acquiring an additional 35,022 shares during the period. Norges Bank purchased a new position in shares of Keros Therapeutics during the fourth quarter worth approximately $1,027,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Keros Therapeutics in the 4th quarter valued at $461,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Down 2.6 %

NASDAQ:KROS opened at $13.65 on Friday. The firm’s fifty day simple moving average is $12.20 and its 200-day simple moving average is $24.71. The stock has a market cap of $554.39 million, a PE ratio of -2.62 and a beta of 1.32. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. During the same period in the prior year, the business posted ($1.21) earnings per share. Equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 20.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Truist Financial lowered their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Wedbush restated a “neutral” rating and issued a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Piper Sandler decreased their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Cantor Fitzgerald lowered Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Finally, Scotiabank decreased their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.67.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.